chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Sex: F
Vaccine: CHIK
Symptoms: Fatigue, Malaise, Pyrexia
Clinical narrative: Fever; The following information was received from a nurse on 31 Dec 2024.  A female of unknown age received one dose of IXCHIQ (prevention of disease caused by chikungunya virus (CHIKV), batch number 24B011) on 13 Dec 2024.   Two days later, on 15 Dec 2024, she experineced fever, fatigue and malaise.   The outcome of the events was reported as not resolved.  Case is linked to case US-INTERCELLP-6624 (husband with same events).; Sender's Comments: Causality assessed as possibly related, as time to onset is plausible (2 days past vaccination) and as Fever and Fatigue are well known for IXCHIQ and Malaise can be seen in the same context as abnormal/ill feeling. All reactions are indicative of a systemic vaccination reaction.
Age: 72.0
Sex: F
Vaccine: COVID19
Symptoms: Blood pressure measurement, Magnetic resonance imaging head, Pain in extremity, Sinusitis
Clinical narrative: it made her arm sore, a "sore muscle"; she also had a sinus infection; This spontaneous case was reported by a patient and describes the occurrence of PAIN IN EXTREMITY (it made her arm sore, a "sore muscle") and SINUSITIS (she also had a sinus infection) in a 72-year-old female patient who received mRNA-1273.712 (SPIKEVAX 2024-2025 PFS) (batch no. unknown) for COVID-19 prophylaxis.     The patient's past medical history included Cataract operation (She had one eye that's good and one eye that isn't but was going to get the other one done.), Colonoscopy (She has had a colonoscopy and a mammogram with the past year : no cancer.) in 2024 and Mammogram (She has had a colonoscopy and a mammogram with the past year : no cancer.) in 2024. Concurrent medical conditions included Spinal stenosis, Ear, nose and throat disorder and Bone densitometry.    On an unknown date, the patient received dose of mRNA-1273.712 (SPIKEVAX 2024-2025 PFS) (unknown route) .5 milliliter. On an unknown date, the patient experienced PAIN IN EXTREMITY (it made her arm sore, a "sore muscle") and SINUSITIS (she also had a sinus infection). At the time of the report, PAIN IN EXTREMITY (it made her arm sore, a "sore muscle") and SINUSITIS (she also had a sinus infection) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Blood pressure measurement: Normal everyday. On an unknown date, Magnetic resonance imaging head: looked for a problem with her left ear vertigo which happened in May.     The action taken with mRNA-1273.712 (SPIKEVAX 2024-2025 PFS) (Unknown) was unknown.     No concomitant medications were reported.  The patient had been fairly healthy. The patient stated she had received 11 COVID vaccines, and the most recent dose of the Spikevax (2024-2025) had been administered 4 months ago. The vaccine had made her arm sore, a sore muscle' for a couple of days. The patient stated she had been in the middle of cataract surgery. She had had a sinus infection and had just been getting over it, but other than that, she had not been sick in years.  The reporter stated she had had ENT issues and had to get knee surgery. She had had bone stuff,' but other than that, she had been completely healthy. She had recently had every test on the planet' the past year. She had had a bone density test with no osteoporosis. The reporter stated that there had been new horrible diseases.  No treatment medications were reported.   This case was linked to MOD-2023-716619 (Patient Link).
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, Disease recurrence, Drug ineffective
Clinical narrative: there's still people getting Covid right now, cause I got it again and even after the boosters; Pfizer Product Name: Boosters/ got it again and event after the boosters; Pfizer Product Name: Boosters/ got it again and event after the boosters; This is a spontaneous report received from a Consumer or other non HCP, Program ID.  A 72-year-old male patient received BNT162b2 (BNT162B2 NOS), as dose number unknown (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (Primary series of immunization completed manufacturer: Unknown), for COVID-19 immunization. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 25Dec2023, outcome "unknown" and all described as "Pfizer Product Name: Boosters/ got it again and event after the boosters"; DISEASE RECURRENCE (medically significant), outcome "unknown", described as "there's still people getting Covid right now, cause I got it again and even after the boosters". Therapeutic measures were taken as a result of drug ineffective, covid-19.  Clinical course: Patient has taken Paxlovid before and report being pleased last time took it. Patient reports now being prescribed the medication again. It was further reported that patient had Paxlovid since he had Covid last year (last Christmas, 25Dec2023), not this past Christmas but the year before, and he used Paxlovid and it was described as a miracle drug. Patient stated that his voice was cracking up now and need to take the medication, his wife is at the pharmacy now and need to have those pills or need to take medication; he reported that there's still people getting Covid right now, cause he got it again and even after the boosters.
Sex: U
Vaccine: COVID19
Symptoms: COVID-19, Disease recurrence, Drug ineffective, SARS-CoV-2 test
Clinical narrative: COVID; COVID; second time tested positive for COVID; This is a spontaneous report received from a Consumer or other non HCP. Other Case identifier(s): MOD-2025-782175 (Moderna).  A patient (age and gender not provided) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), in Nov2022 as dose 5 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation; BNT162b2 (BNT162B2), in Feb2021 as dose 1, single (Batch/Lot number: unknown), in Mar2021 as dose 2, single (Batch/Lot number: unknown), in Sep2021 as dose 3 (booster), single (Batch/Lot number: unknown) and in Apr2022 as dose 4 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "battled leukemia" (unspecified if ongoing), notes: for close to 10 years and was on a drug trial through. The patient's concomitant medications were not reported. Past drug history included: Protonix, reaction(s): "GERD"; Olmesartan, reaction(s): "high blood pressure", notes: 40 mg once daily; Amlodipine, reaction(s): "high blood pressure", notes: 10 mg once daily The following information was reported: DISEASE RECURRENCE (medically significant) with onset 2023, outcome "recovered", described as "second time tested positive for COVID"; DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "recovered" and all described as "COVID". The clinical course was reported as follows: The patient tested positive for COVID twice. The first time got COVID, took PAXLOVID and the PAXLOVID gave more side effects than the COVID virus did. The second time tested positive for COVID (at the end of 2023) they attempted to find a smaller/ pediatric dose of PAXLOVID but by the time they found it, no longer had any symptoms. The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (unspecified date) Positive; (2023) Positive. Therapeutic measures were taken as a result of drug ineffective, covid-19.  No follow-up attempts are possible. Batch/lot number is not provided, and it cannot be obtained.
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, Drug ineffective
Clinical narrative: talked someone earlier about Paxlovid/prescription is for her husband/took 3 Pfizer COVID vaccines; talked someone earlier about Paxlovid/prescription is for her husband/took 3 Pfizer COVID vaccines; This is a spontaneous report received from a Consumer or other non HCP, Program ID.  A 78-year-old male patient received BNT162b2 (BNT162B2), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown) and in Oct2021 as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "talked someone earlier about Paxlovid/prescription is for her husband/took 3 Pfizer COVID vaccines". Therapeutic measures were taken as a result of drug ineffective, covid-19. The clinical course was reported as follows: Patient's wife reported that her husband was asleep; he was just at home sick. Reporter and her husband took 3 Pfizer COVID vaccines, last one probably in the fall 2021, Oct2021.
Sex: M
Vaccine: UNK
Symptoms: Influenza
Clinical narrative: Seasonal influenza; This spontaneous case, initially received on 07-Feb-2025, was reported by a non health professional and concerns a male patient with unknown age.  Medical history and concomitant medications were reported as unknown.  Administration of company suspect drug: On an unknown date in Oct-2024 or Nov-2024, the patient received Flucelvax (TIV) for Influenza vaccination, Dose regimen: 0.5 ml, route of administration and anatomical location: not reported. Lot number: not reported but would be requested upon follow-up.    No additional suspect drugs.  Adverse reactions/events and outcomes: On 29-Jan-2025, the patient experienced Seasonal influenza (Medically Significant, outcome: Not Reported, stop date: 29-Jan-2025).  It was reported that In October or November of 2024, the patient received the  Flucelvax vaccine and he diagnosed with seasonal influenza on 29-Jan-2025.  'Case was upgraded to serious upon company assessment of the reported event Seasonal influenza clinical significance'  Flucelvax (TIV) action taken: Not Applicable  Reporter assessment:  The reporter considered the event as non-serious and did not provide a causality assessment for event; Reporter's Comments: Causality: Due to the spontaneous nature of the case, it is considered related for reporting purposes. Causal association cannot be completely ruled out for the events in view of insufficient information (events onset date, temporality, relevant medical history,nclear etiology).
Age: 33.0
Sex: F
Vaccine: HEP
Symptoms: Exposure via skin contact, Syringe issue, Underdose
Clinical narrative: administration of an incomplete Engerix-B dose to an adult patient; an unknown volume of the vaccine dripped over the patient´s arm; an unknown volume of the vaccine dripped over the patient´s arm; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of incomplete dose administered in a 33-year-old female patient who received HBV (Engerix B) (batch number 92NK2, expiry date 29-SEP-2026) for prophylaxis.   On 26-JAN-2025, the patient received Engerix B. On 26-JAN-2025, an unknown time after receiving Engerix B, the patient experienced incomplete dose administered (Verbatim: administration of an incomplete Engerix-B dose to an adult patient), exposure via skin contact (Verbatim: an unknown volume of the vaccine dripped over the patient´s arm) and inadvertent exposure to vaccine (Verbatim: an unknown volume of the vaccine dripped over the patient´s arm). The outcome of the incomplete dose administered, exposure via skin contact and inadvertent exposure to vaccine were not applicable.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date: 27-JAN-2025 A pharmacist called to report the administration of an incomplete Engerix-B dose to a patient, which led to an incomplete dose administration. The pharmacist mentioned that during the administration an unknown volume of the vaccine dripped over the patient's arm, which led to an inadvertent exposure to vaccine and exposure via skin contact. The reporter asked if patient should be revaccinated.
Age: 0.17
Sex: F
Vaccine: DTPPVHBHPB
Symptoms: Injected limb mobility decreased, Injection site swelling, Irritable bowel syndrome
Clinical narrative: leg swelling, entire leg, unable to move leg, fussy/irritable
Age: 4.0
Sex: M
Vaccine: DTAPIPV, HEPA, MMRV
Symptoms: Dermatitis bullous, Rash papular, Rhinorrhoea, Varicella post vaccine
Clinical narrative: Developed rhinorrhea and papular-vesicular-bullous rash 3d after vaccination - suspect post-vaccination varicella
Age: 74.0
Sex: M
Vaccine: TDAP
Symptoms: Rash
Clinical narrative: Patient reported to the pharmacy that he developed a rash on his hands and head that began several months after he received the vaccine.  He reported it 2 years after the vaccine was given.
Age: 72.0
Sex: M
Vaccine: COVID19
Symptoms: Injection site bruising
Clinical narrative: The patient came to the pharmacy on 2/19/25 to show photos of large black and blue bruising around the injection site
Age: 58.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, COVID-19, Fatigue, Gait disturbance, Impaired work ability
Clinical narrative: Vaccine given at 4 pm. Drove home which was 30 minutes away. Around 5:30pm I decided to do my workout. My arm was sore but nothing to be alarmed about. I did everything for the beginning and standing part. I then went to the floor to do my floor workout. It is a good thing I did. I only remember laying down. I completely passed out. I have never passed out before. I woke up about 30 minutes later and I was sick as a dog. I had a high fever and I hurt from head to toe. I was eating the ibuprofen all weekend and it took about 3 days before I began to feel a little better. I had to miss work. This was the second injection. I did not have any reaction to the first one. I now know I actually had Covid. Since the vaccines, I have had Covid twice. So much for the stupid vaccine. Every time I get it I have adverse symptoms that are long lasting. Especially low or no energy. I find it hard to even go up stairs. Complete fatigue. I still struggle on and off with that without being sick. I know it is a leftover from the vaccines.
Age: 58.0
Sex: F
Vaccine: COVID19
Symptoms: Loss of consciousness, Malaise, Pain, Pain in extremity, Pyrexia
Clinical narrative: Vaccine given at 4 pm. Drove home which was 30 minutes away. Around 5:30pm I decided to do my workout. My arm was sore but nothing to be alarmed about. I did everything for the beginning and standing part. I then went to the floor to do my floor workout. It is a good thing I did. I only remember laying down. I completely passed out. I have never passed out before. I woke up about 30 minutes later and I was sick as a dog. I had a high fever and I hurt from head to toe. I was eating the ibuprofen all weekend and it took about 3 days before I began to feel a little better. I had to miss work. This was the second injection. I did not have any reaction to the first one. I now know I actually had Covid. Since the vaccines, I have had Covid twice. So much for the stupid vaccine. Every time I get it I have adverse symptoms that are long lasting. Especially low or no energy. I find it hard to even go up stairs. Complete fatigue. I still struggle on and off with that without being sick. I know it is a leftover from the vaccines.
Age: 73.0
Sex: M
Vaccine: VARZOS
Symptoms: Chills, Flank pain, Renal pain
Clinical narrative: Chills, uncontrolled shivering and kidney/flank pain.
Age: 64.0
Sex: M
Vaccine: COVID19
Symptoms: Atrial fibrillation, Balance disorder, Brain fog, Cardiac ablation, Cerebrovascular accident
Clinical narrative: Suffered stroke on 8/9/2021.  Developed A Fib, sleep apnea,  vertigo, paralyzed vocal cord, numbness on left side of body, major balance issues. Spent 3 weeks in the hospital, then had one year of physical therapy. Made significant recovery but still suffer from balance issues, brain fog  and numbness on left side of body.
Age: 64.0
Sex: M
Vaccine: COVID19
Symptoms: Hypoaesthesia, Sleep apnoea syndrome, Vertigo, Vocal cord paralysis
Clinical narrative: Suffered stroke on 8/9/2021.  Developed A Fib, sleep apnea,  vertigo, paralyzed vocal cord, numbness on left side of body, major balance issues. Spent 3 weeks in the hospital, then had one year of physical therapy. Made significant recovery but still suffer from balance issues, brain fog  and numbness on left side of body.
Age: 22.0
Sex: M
Vaccine: COVID19, HEP, MMR, TDAP
Symptoms: Syncope, Urinary incontinence
Clinical narrative: Patient fainted and urinated themselves about a minute after completing vaccines
Age: 53.0
Sex: F
Vaccine: TD
Symptoms: Cervical vertebral fracture, Exercise tolerance decreased, Loss of consciousness, Palpitations, Postural orthostatic tachycardia syndrome
Clinical narrative: Syncope with exercise and palpitations. I passed out while riding my bicycle and broke my neck etc. I almost died. I had a POTs type syndrome. I got the TD again this year after a large puncture wound and developed POTs again about 10 days after the shot. I would continually pass out if I tried to exercise or put forth any effort . It is somewhat better now but still lots of palpitations. I was curious to if I had a TD shot just prior to my accident and sure enough I did. I am obviously not ever getting another TD. I had a reaction a long time ago with a drop in B/p lasting a week and thought it was the pertussis component. Apparently not.  Feel free to call with ?. I was an ED RN prior to my accident and disability.
Age: 53.0
Sex: F
Vaccine: TD
Symptoms: Road traffic accident, Syncope, Wound
Clinical narrative: Syncope with exercise and palpitations. I passed out while riding my bicycle and broke my neck etc. I almost died. I had a POTs type syndrome. I got the TD again this year after a large puncture wound and developed POTs again about 10 days after the shot. I would continually pass out if I tried to exercise or put forth any effort . It is somewhat better now but still lots of palpitations. I was curious to if I had a TD shot just prior to my accident and sure enough I did. I am obviously not ever getting another TD. I had a reaction a long time ago with a drop in B/p lasting a week and thought it was the pertussis component. Apparently not.  Feel free to call with ?. I was an ED RN prior to my accident and disability.
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Erythema, Insomnia, Neutrophil count decreased, Pruritus
Clinical narrative: rash, itching, over 90% of body, fever, chills, lack of sleep, thickened skin, hyperpigmentation, erythemia, White blood cells and nuetrophil levels low - this has been happening from time of vaccine to present day
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia, Rash, Skin hyperpigmentation, Skin hypertrophy, White blood cell count decreased
Clinical narrative: rash, itching, over 90% of body, fever, chills, lack of sleep, thickened skin, hyperpigmentation, erythemia, White blood cells and nuetrophil levels low - this has been happening from time of vaccine to present day
Age: 69.0
Sex: F
Vaccine: FLU3
Symptoms: Dizziness, Malaise, Nausea, Vomiting
Clinical narrative: When I woke up Wednesday I was dizzy, rather quickly felt nauseous and within about 3 hours, I was sick (vomited.) I continued to be dizzy for the next 3 days and finally felt better on Sunday.  (Please note :  I am not sure of the exact Flu shot I received but I *think* it was the Seasonal Influenza High-dose Fluzone - but pharmacy would know for sure.  I can't call to ask since the Pharmacy is closed now.)
Age: 64.0
Sex: F
Vaccine: HEPA
Symptoms: Inappropriate schedule of product administration
Clinical narrative: Administration error given 30 days after prior dose
Age: 53.0
Sex: F
Vaccine: COVID19, VARZOS
Symptoms: Tinnitus
Clinical narrative: Tinnitus for the first time in my life and appears to be permanent
Age: 6.0
Sex: M
Vaccine: MMRV
Symptoms: Product storage error
Clinical narrative: On October 1, 2024 clinic received a shipment of COVID vaccine that needed to be stored in the freezer. There was no room in the freezer to accommodate the shipment. The following document was found on the FDA website: file:///U:/Package-Insert=Refrigerator-Stable-Formulation-ProQuad.pdf It was assumed that ProQuad could be stored in both the freezer and refrigerator and both State and Private ProQuad were moved to the refrigerators where they remained within normal refrigerated temperature range until administration. The dose of MMRV administered to this client was moved from the freezer to refrigerator on October 1, 2024 and refrigerated until administration on November 21, 2024.
Age: 5.0
Sex: M
Vaccine: DTAPIPV, MMRV
Symptoms: Product storage error
Clinical narrative: On October 1, 2024 clinic received a shipment of COVID vaccine that needed to be stored in the freezer. There was no rom in the freezer to accommodate the shipment. The following document was found on the FDA website: file:///U:Package-Insert-Refrigerator-Stable-Formulation-Proquad.pdf. It was assumed that ProQuad could be stored in both the freezer and refrigerator and both State and Private ProQuad were moved to the refrigerators where they remained within normal refrigerated temperature range until administration. The dose of MMRV administered to this client was one that was moved from freezer to refrigerator on October 1, 2024 until administered on October 3, 2024.
Age: 7.0
Sex: F
Vaccine: IPV, MMRV, TDAP
Symptoms: Product storage error
Clinical narrative: On October 1, 2024 clinic received a shipment of COVID vaccine that needed to be stored in the freezer. There was no room in the freezer to accommodate the shipment. The following document was found on the FDA website: file:///U:Package-Insert-Refrigerator-Stable-Formulation-Proquad.pdf. It was assumed that ProQuad could be stored in both the freezer and refrigerator and both State and Private ProQuad were moved to the refrigerators where they remained within normal refrigerated temperature range until administration. The dose of MMRV administered to this client was received on November 13, 2024 and stored in the refrigerator until administered on January 8, 2025.
Age: 12.0
Sex: M
Vaccine: MMRV, UNK
Symptoms: Product storage error
Clinical narrative: On October 1, 2024 clinic received a shipment of COVID vaccine that needed to be stored in the freezer. There was no room in the freezer to accommodate the shipment. The following document was found on the FDA website: file:///U:Package-Insert-Refrigerator-Stable-Formulation-Proquad.pdf. It was assumed that ProQuad could be stored in both the freezer and refrigerator and both State and Private ProQuad were moved to the refrigerators where they remained within normal refrigerated temperature range until administration. The dose of MMRV administered to this client was received on January 13, 2025 and stored in the refrigerator until administered on January 13, 2025.
Age: 12.0
Sex: M
Vaccine: MMRV, UNK
Symptoms: No adverse event, Product storage error
Clinical narrative: On October 1, 2024 clinic received a shipment of COVID vaccine that needed to be stored in the freezer. There was no room in the freezer to accommodate the shipment. The following document was found on the FDA website: file:///U:Package-Insert-Refrigerator-Stable-Formulation-Proquad.pdf. It was assumed that ProQuad could be stored in both the freezer and refrigerator and both State and Private ProQuad were moved to the refrigerators where they remained within normal refrigerated temperature range until administration. The dose of MMRV administered to this client was received on January 13, 2025 and stored in the refrigerator until administered on January 13, 2025.
Age: 10.0
Sex: F
Vaccine: HEP, HEPA, HPV9, MMRV, MMRV, MMRV
Symptoms: Product storage error
Clinical narrative: On October 1, 2024 PH received a shipment of COVID vaccine that needed to be stored in the freezer. There was no room in the freezer to accomodate the shipment. The following document was found on the FDA website. It was assumed that ProQuad could be stored in both the freezer and refrigerator and both state and private ProQuad were moved to the refrigerators where they remained within normal refrigerated temperature range until administration. The dose of MMRV administered to this client was one that was moved from freezer to refrigerator on October 1, 2024 until administered on January 16, 2025.
Age: 10.0
Sex: F
Vaccine: HEP, HEPA, HPV9, MMRV, MMRV, MMRV
Symptoms: No adverse event, Product storage error
Clinical narrative: On October 1, 2024 PH received a shipment of COVID vaccine that needed to be stored in the freezer. There was no room in the freezer to accomodate the shipment. The following document was found on the FDA website. It was assumed that ProQuad could be stored in both the freezer and refrigerator and both state and private ProQuad were moved to the refrigerators where they remained within normal refrigerated temperature range until administration. The dose of MMRV administered to this client was one that was moved from freezer to refrigerator on October 1, 2024 until administered on January 16, 2025.
Age: 12.0
Sex: M
Vaccine: HEP, IPV, MMRV, MNQ, TDAP, UNK
Symptoms: Product storage error
Clinical narrative: On October 1, 2024 clinic received a shipment of COVID vaccine that needed to be stored in the freezer. There was no room in the freezer to accommodate the shipment. The following document was found on the FDA website: file:///U:Package-Insert-Refrigerator-Stable-Formulation-Proquad.pdf. It was assumed that ProQuad could be stored in both the freezer and refrigerator and both State and Private ProQuad were moved to the refrigerators where they remained within normal refrigerated temperature range until administration. The dose of MMRV administered to this client was received and refrigerated on January 13, 2025.
Age: 12.0
Sex: M
Vaccine: HEP, IPV, MMRV, MNQ, TDAP, UNK
Symptoms: No adverse event, Product storage error
Clinical narrative: On October 1, 2024 clinic received a shipment of COVID vaccine that needed to be stored in the freezer. There was no room in the freezer to accommodate the shipment. The following document was found on the FDA website: file:///U:Package-Insert-Refrigerator-Stable-Formulation-Proquad.pdf. It was assumed that ProQuad could be stored in both the freezer and refrigerator and both State and Private ProQuad were moved to the refrigerators where they remained within normal refrigerated temperature range until administration. The dose of MMRV administered to this client was received and refrigerated on January 13, 2025.
Age: 11.0
Sex: F
Vaccine: FLUN4, HEPA, HPV9, MMRV, MMRV, MMRV
Symptoms: Product storage error
Clinical narrative: On October 1, 2024 clinic received a shipment of COVID vaccine that needed to be stored in the freezer. There was no room in the freezer to accomodate the shipment. The following document was found on the FDA website It was assumed that ProQuad could be stored in both the freezer and refrigerator and both State and Private ProQuad were moved to the refrigerators where they remained within normal refrigerated temperature range until administration. The dose of MMRV administered to this client was moved from the freezer to refrigerator on October 1, 2024 and refrigerated until administration on November 21, 2024.
Age: 11.0
Sex: F
Vaccine: FLUN4, HEPA, HPV9, MMRV, MMRV, MMRV
Symptoms: No adverse event, Product storage error
Clinical narrative: On October 1, 2024 clinic received a shipment of COVID vaccine that needed to be stored in the freezer. There was no room in the freezer to accomodate the shipment. The following document was found on the FDA website It was assumed that ProQuad could be stored in both the freezer and refrigerator and both State and Private ProQuad were moved to the refrigerators where they remained within normal refrigerated temperature range until administration. The dose of MMRV administered to this client was moved from the freezer to refrigerator on October 1, 2024 and refrigerated until administration on November 21, 2024.
Age: 11.0
Sex: F
Vaccine: FLUC4, HPV9, MMRV, MNQ
Symptoms: Product storage error
Clinical narrative: On October 1, 2024 PH received a shipment of COVID vaccine that needed to be stored in the freezer. There was no room in the freezer to accomodate the shipment. The following document was found on the FDA website It was assumed that ProQuad could be stored in both the freezer and refrigerator and both State and Private ProQuad were moved to the refrigerators where they remained within normal refrigerated temperature range until administration. The dose of MMRV administered to this client was one that was removed from the freezer to the refrigerator on October 1, 2024.
Age: 5.0
Sex: M
Vaccine: MMRV
Symptoms: Product storage error
Clinical narrative: On October 1, 2024 PH received a shipment of COVID vaccine that needed to be stored in the freezer. There was no room in the freezer to accomodate the shipment. The following document was found on the FDA website It was assumed that the ProQuad could be stored in both the freezer and refrigerator and both State and Private ProQuad were moved to the refrigerators where they remained within normal refrigerated temperature range until administration. The dose of MMRV admin to this client was one that was removed from the freezer to the refrigerator on October 1, 2024.
Age: 5.0
Sex: F
Vaccine: DTAPIPV, HEPA, MMRV, UNK
Symptoms: Product storage error
Clinical narrative: On October 1, 2024 clinic received a shipment of COVID vaccine that needed to be stored in the freezer. There was no room in the freezer to accomodate the shipment. The following document was found on the FDA website It was assumed that ProQuad could be stored in both the freezer and refrigerator and both State and Private ProQuad were moved to the refrigerators where they remained within normal refrigerated temperature range until administration. The dose of MMRV administered to this client was received on January 13, 2025 and stored in the refrigerator until administered on February 5, 2025.
Age: 5.0
Sex: F
Vaccine: DTAPIPV, HEPA, MMRV, UNK
Symptoms: No adverse event, Product storage error
Clinical narrative: On October 1, 2024 clinic received a shipment of COVID vaccine that needed to be stored in the freezer. There was no room in the freezer to accomodate the shipment. The following document was found on the FDA website It was assumed that ProQuad could be stored in both the freezer and refrigerator and both State and Private ProQuad were moved to the refrigerators where they remained within normal refrigerated temperature range until administration. The dose of MMRV administered to this client was received on January 13, 2025 and stored in the refrigerator until administered on February 5, 2025.
Age: 6.0
Sex: F
Vaccine: COVID19, IPV, MMRV, UNK
Symptoms: Product storage error
Clinical narrative: On October 1, 2024 clinic received a shipment of COVID vaccine that needed to be stored in the freezer. There was no room in the freezer to accomodate the shipment. The following document was found on the FDA website It was assumed that ProQuad could be stored in both the freezer and refrigerator and both State and Private ProQuad were moved to the refrigerators where they remained within normal refrigerated temperature range until administration. The dose of MMRV administered to this client was moved from the freezer to refrigerator on October 1, 2024 and refrigerated until administration on January 9, 2025.
Age: 6.0
Sex: F
Vaccine: COVID19, IPV, MMRV, UNK
Symptoms: No adverse event, Product storage error
Clinical narrative: On October 1, 2024 clinic received a shipment of COVID vaccine that needed to be stored in the freezer. There was no room in the freezer to accomodate the shipment. The following document was found on the FDA website It was assumed that ProQuad could be stored in both the freezer and refrigerator and both State and Private ProQuad were moved to the refrigerators where they remained within normal refrigerated temperature range until administration. The dose of MMRV administered to this client was moved from the freezer to refrigerator on October 1, 2024 and refrigerated until administration on January 9, 2025.
Age: 6.0
Sex: F
Vaccine: COVID19, IPV, MMRV, COVID19, IPV, MMRV, UNK
Symptoms: Product storage error
Clinical narrative: On October 1, 2024 PH received a shipment of COVID vaccine that needed to be stored in the freezer. There was no room in the freezer to accomodate the shipment. The following document was found on the FDA website. It was assumed that ProQuad could be stored in both the freezer and refrigerator and both state and private Proquad were moved to the refrigerators where they remained within normal refrigerated temperature range until administration. The dose of MMRV administered to this client was one that was removed from the freezer to the refrigerator on October 1, 2024.
Age: 6.0
Sex: F
Vaccine: COVID19, IPV, MMRV, COVID19, IPV, MMRV, UNK
Symptoms: No adverse event, Product storage error
Clinical narrative: On October 1, 2024 PH received a shipment of COVID vaccine that needed to be stored in the freezer. There was no room in the freezer to accomodate the shipment. The following document was found on the FDA website. It was assumed that ProQuad could be stored in both the freezer and refrigerator and both state and private Proquad were moved to the refrigerators where they remained within normal refrigerated temperature range until administration. The dose of MMRV administered to this client was one that was removed from the freezer to the refrigerator on October 1, 2024.
Age: 8.0
Sex: M
Vaccine: FLUC4, HEP, MMRV
Symptoms: Product storage error
Clinical narrative: On October 1, 2024 clinic received a shipment of COVID vaccine that needed to be stored in the freezer. There was no room in the freezer to accomodate the shipment. The following document was found on the FDA website It was assumed that ProQuad could be stored in both the freezer and refrigerator and both State and Private ProQuad were moved to the refrigerators where they remained within normal refrigerated temperature range until administration. The dose of MMRV administered to this client was moved from the freezer to refrigerator on October 1, 2024 and refrigerated until administration on December 5, 2024.
Age: 9.0
Sex: M
Vaccine: FLUN4, HEPA, MMRV
Symptoms: Product storage error
Clinical narrative: On October 1, 2024 PH received a shipment of COVID vaccine that needed to be stored in the freezer. There was no room in the freezer to accomodate the shipment. The following document was found on the FDA website. It was assumed that ProQuad could be stored in both the freezer and refrigerator and both state and private ProQuad were moved to the refrigerators where they remained within normal refrigerated temperature range until administration. The dose of MMRV administered to this client was moved from the freezer to refrigerator on October 1, 2024 and refrigerated until administration on October 21, 2024.
Age: 9.0
Sex: M
Vaccine: HEP, IPV, MMRV, TDAP, HEP, IPV, TDAP, UNK, UNK
Symptoms: Product storage error
Clinical narrative: On October 1, 2024 clinic received a shipment of COVID vaccine that needed to be stored in the freezer. There was no room in the freezer to accomodate the shipment. The following document was found on the FDA website It was assumed that ProQuad could be stored in both the freezer and refrigerator and both State and Private ProQuad were moved to the refrigerators where they remained within normal refrigerated temperature range until administration. The dose of MMRV administered to this client was received on January 13, 2025 and refrigerated until administered on January 31, 2025.
Age: 9.0
Sex: M
Vaccine: HEP, IPV, MMRV, TDAP, HEP, IPV, TDAP, UNK, UNK
Symptoms: No adverse event, Product storage error
Clinical narrative: On October 1, 2024 clinic received a shipment of COVID vaccine that needed to be stored in the freezer. There was no room in the freezer to accomodate the shipment. The following document was found on the FDA website It was assumed that ProQuad could be stored in both the freezer and refrigerator and both State and Private ProQuad were moved to the refrigerators where they remained within normal refrigerated temperature range until administration. The dose of MMRV administered to this client was received on January 13, 2025 and refrigerated until administered on January 31, 2025.
Age: 10.0
Sex: F
Vaccine: HEP, IPV, MMRV, TDAP, MMRV, UNK
Symptoms: Product storage error
Clinical narrative: On October 1, 2024 clinic received a shipment of COVID vaccine that needed to be stored in the freezer. There was no room in the freezer to accomodate the shipment. The following document was found on the FDA website It was assumed that ProQuad could be stored in both the freezer and refrigerator and both State and Private ProQuad were moved to the refrigerators where they remained within normal refrigerated temperature range until administration. The dose of MMRV administered to this client was one that was moved from the freezer to refrigerator on October 1, 2024 until administered on November 19, 2024.
Age: 10.0
Sex: F
Vaccine: HEP, IPV, MMRV, TDAP, MMRV, UNK
Symptoms: No adverse event, Product storage error
Clinical narrative: On October 1, 2024 clinic received a shipment of COVID vaccine that needed to be stored in the freezer. There was no room in the freezer to accomodate the shipment. The following document was found on the FDA website It was assumed that ProQuad could be stored in both the freezer and refrigerator and both State and Private ProQuad were moved to the refrigerators where they remained within normal refrigerated temperature range until administration. The dose of MMRV administered to this client was one that was moved from the freezer to refrigerator on October 1, 2024 until administered on November 19, 2024.
Age: 12.0
Sex: M
Vaccine: FLU4, HEP, HEPA, MMRV, MMRV, MMRV
Symptoms: Product storage error
Clinical narrative: On October 1, 2024 clinic received a shipment of COVID vaccine that needed to be stored in the freezer. There was no room in the freezer to accomodate the shipment. The following document was found on the FDA website Unaware that there were two ProQuad products licensed by the FDA, it was assumed that the ProQuad we received could be refrigerated and both State and Private ProQuad were moved to the refrigerators where they remained within normal refrigerated temperature range (36 to 46 degrees Fahrenheit) until administration. The dose of MMRV admin to this client arrived to our facility on 11/13/24 and was refrigerated until admin on 1/6/25.
Age: 12.0
Sex: M
Vaccine: FLU4, HEP, HEPA, MMRV, MMRV, MMRV
Symptoms: No adverse event, Product storage error
Clinical narrative: On October 1, 2024 clinic received a shipment of COVID vaccine that needed to be stored in the freezer. There was no room in the freezer to accomodate the shipment. The following document was found on the FDA website Unaware that there were two ProQuad products licensed by the FDA, it was assumed that the ProQuad we received could be refrigerated and both State and Private ProQuad were moved to the refrigerators where they remained within normal refrigerated temperature range (36 to 46 degrees Fahrenheit) until administration. The dose of MMRV admin to this client arrived to our facility on 11/13/24 and was refrigerated until admin on 1/6/25.
Age: 8.0
Sex: F
Vaccine: FLUC4, HEPA, MMRV
Symptoms: Product storage error
Clinical narrative: On October 1, 2024 PH received a shipment of COVID vaccine that needed to be stored in the freezer. There was no room in the freezer to accomodate the shipment. The following document was found on the FDA website. Unaware that there were two Proquad products licensed by the FDA, it was assumed that the Proquad we received could be refrigerated and both state and private Proquad were moved to the refrigerators where they remained within normal refrigerated temperature range (35 to 46 degree Fahrenheit) until administration. The dose of MMRV admin to this client was refrigerated on 10/1 until admin on 12/9/24.
Age: 7.0
Sex: F
Vaccine: FLU4, HEP, HEPA, MMRV
Symptoms: Product storage error
Clinical narrative: On October 1, 2024 PH received a shipment of COVID vaccine that needed to be stored in the freezer. There was no room in the freezer to accomodate the shipment. The following document was found on the FDA website. Unaware that there were two ProQuad products licensed by the FDA, it was assume that the Proquad we received could be refrigerated and both state and private Proquad were moved to the refrigerators where they remained within normal refrigerated temperature range (36 to 46 degrees Fahrenheit) until administration. The dose of MMRV admin to this client arrived to our facility on 11/13/24 and was refrigerated until admin on 1/8/25.
Age: 5.0
Sex: M
Vaccine: FLUC4, MMRV, UNK
Symptoms: Product storage error
Clinical narrative: On October 1, 2024, clinic received a shipment of COVID vaccine that needed to be stored in the freezer. There was no room in the freezer to accomodate the shipment. The following document was found on the FDA website. Unaware that there were two ProQuad products licensed by the FDA, It was assumed that the ProQuad we received could be refrigerated and both State and Private ProQuad were moved to the refrigerators where they remained within normal refrigerated temperature range (36 to 46 degrees Fahrenheit) until administration. The dose of MMRV admin to this client arrived at our facility on 11/13/24 and was refrigerateduntil admin on 12/18/24.
Age: 5.0
Sex: M
Vaccine: FLUC4, MMRV, UNK
Symptoms: No adverse event, Product storage error
Clinical narrative: On October 1, 2024, clinic received a shipment of COVID vaccine that needed to be stored in the freezer. There was no room in the freezer to accomodate the shipment. The following document was found on the FDA website. Unaware that there were two ProQuad products licensed by the FDA, It was assumed that the ProQuad we received could be refrigerated and both State and Private ProQuad were moved to the refrigerators where they remained within normal refrigerated temperature range (36 to 46 degrees Fahrenheit) until administration. The dose of MMRV admin to this client arrived at our facility on 11/13/24 and was refrigerateduntil admin on 12/18/24.
Age: 11.0
Sex: F
Vaccine: HEP, IPV, MMRV, MNQ, TDAP
Symptoms: Product storage error
Clinical narrative: On October 1, 2024, clinic received a shipment of COVID vaccine that needed to be stored in the freezer. There was no room in the freezer to accomodate the shipment. The following document was found on the FDA website. Unaware that there were two ProQuad products licensed by the FDA, It was assumed that the ProQuad we received could be refrigerated and both State and Private ProQuad were moved to the refrigerators where they remained within normal refrigerated temperature range (36 to 46 degrees Fahrenheit) until administration. The dose of MMRV admin to this client arrived to our facility on 1/13/24 and was refrigerated until admin on 1/29/25.
Age: 10.0
Sex: M
Vaccine: COVID19, HEP, HEPA, MMRV
Symptoms: Product storage error
Clinical narrative: On October 1, 2024 clinic received a shipment of COVID vaccine that needed to be stored in the freezer. There was no room in the freezer to accomodate the shipment. The following document was found on the FDA website Unaware that there were two ProQuad products licensed by the FDA, It was assumed that the ProQuad we received could be refrigerated and both State and Private ProQuad were moved to the refrigerators where they remained within normal refrigerated temperature range (36 to 46 degrees Fahrenheit) until administration. The dose of MMRV admin to this client was refrigerated on 11/13/24 until admin on 1/8/25.
Age: 6.0
Sex: F
Vaccine: DTAPHEPBIP, HEPA, MMRV
Symptoms: Product storage error
Clinical narrative: On October 1, 2024, clinic received a shipment of COVID vaccine that needed to be stored in the freezer. There was no room in the freezer to accomodate the shipment. The following document was found on the FDA website Unaware that there were two ProQuad products licensed by the FDA, It was assumed that the ProQuad we received could be refrigerated and both State and Private ProQuad were moved to the refrigerators where they remained within normal refrigerated temperature range (36 to 46 degrees Fahrenheit) until administration. The dose of MMRV admin to this client was refrigerated on 10/1/24 until admin on 12/4/24.
Age: 12.0
Sex: M
Vaccine: COVID19, FLU4, HEP, HEPA, HPV9, IPV, MMRV, TDAP, HEP, HEPA, HPV9, UNK
Symptoms: Product storage error
Clinical narrative: On October 1, 2024, clinic received a shipment of COVID vaccine that needed to be stored in the freezer. There was no room in the freezer to accomodate the shipment. The following document was found on the FDA website Unaware that there were two ProQuad products licensed by the FDA, It was assumed that the ProQuad we received could be refrigerated and both State and Private ProQuad were moved to the refrigerators where they remained within normal refrigerated temperature range (36 to 46 degrees Fahrenheit) until administration. The dose of MMRV admin to this client arrived at our facility on 11/13/24 and was refrigerateduntil admin on 1/8/25.
Age: 12.0
Sex: M
Vaccine: COVID19, FLU4, HEP, HEPA, HPV9, IPV, MMRV, TDAP, HEP, HEPA, HPV9, UNK
Symptoms: No adverse event, Product storage error
Clinical narrative: On October 1, 2024, clinic received a shipment of COVID vaccine that needed to be stored in the freezer. There was no room in the freezer to accomodate the shipment. The following document was found on the FDA website Unaware that there were two ProQuad products licensed by the FDA, It was assumed that the ProQuad we received could be refrigerated and both State and Private ProQuad were moved to the refrigerators where they remained within normal refrigerated temperature range (36 to 46 degrees Fahrenheit) until administration. The dose of MMRV admin to this client arrived at our facility on 11/13/24 and was refrigerateduntil admin on 1/8/25.
Age: 5.0
Sex: M
Vaccine: HEPA, MMRV
Symptoms: Product storage error
Clinical narrative: On October 1, 2024, clinic received a shipment of COVID vaccine that needed to be stored in the freezer. There was no room in the freezer to accomodate the shipment. The following document was found on the FDA website Unaware that there were two ProQuad products licensed by the FDA, It was assumed that the ProQuad we received could be refrigerated and both State and Private ProQuad were moved to the refrigerators where they remained within normal refrigerated temperature range (36 to 46 degrees Fahrenheit) until administration. The dose of MMRV admin to this client at our facility on 1/13/25 and was refrigerated until admin on 2/7/25.
Age: 2.0
Sex: M
Vaccine: DTPPVHBHPB, FLUN4, HEPA, MMRV, PNC20
Symptoms: Product storage error
Clinical narrative: On October 1, 2024, clinic received a shipment of COVID vaccine that needed to be stored in the freezer. There was no room in the freezer to accomodate the shipment. The following document was found on the FDA website Unaware that there were two ProQuad products licensed by the FDA, It was assumed that the ProQuad we received could be refrigerated and both State and Private ProQuad were moved to the refrigerators where they remained within normal refrigerated temperature range (36 to 46 degrees Fahrenheit) until administration. The dose of MMRV admin to this client was refrigerated on 10/1/24 until admin on 11/20/24.
Age: 6.0
Sex: M
Vaccine: DTAP, HEP, MMRV
Symptoms: Product storage error
Clinical narrative: On October 1, 2024, clinic received a shipment of COVID vaccine that needed to be stored in the freezer. There was no room in the freezer to accomodate the shipment. The following document was found on the FDA website. Unaware that there were two ProQuad products licensed by the FDA, It was assumed that the ProQuad we received could be refrigerated and both State and Private ProQuad were moved to the refrigerators where they remained within normal refrigerated temperature range (36 to 46 degrees Fahrenheit) until administration. The dose of MMRV admin to this client arrived to our facility on 1/13/25 and was refrigerated until admin on 1/23/25.